ResMed (RMD) CFO reports option exercise and share sale under 10b5-1 plan

Rhea-AI Filing Summary

ResMed Inc. Chief Financial Officer Brett Sandercock reported insider transactions on 10/01/2025. Under a Rule 10b5-1 plan adopted 2/19/2025, he acquired 2,000 common shares by exercise of options at a strike of $101.64 and sold 3,000 shares at an average price of $274.36, leaving him with 86,745 shares beneficially owned after the transactions. The exercised options were originally exercisable beginning 11/11/2019 and expire 11/14/2025; the options vest 1/3 per year. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan, providing pre-established trade intent
• Timely reporting with Form 4 signed and filed promptly (signed 10/02/2025)

Negative

• Net disposal of shares on 10/01/2025 (sold 3,000, acquired 2,000) reducing beneficial holdings
• Options expire soon on 11/14/2025, indicating limited remaining exercise window

Insights

Insider Transactions Specialist

Insider sold more shares than exercised under a pre-established 10b5-1 plan.

The Form 4 shows a contemporaneous exercise of 2,000 options at $101.64 and a sale of 3,000 shares at $274.36 on 10/01/2025. Both moves are reported as executed under a Rule 10b5-1 plan adopted 2/19/2025, which documents a predefined trading schedule and can limit questions about opportunistic timing.

This pattern — exercising options and selling a larger parcel — is a common liquidity and tax-management activity for executives. The remaining beneficial ownership of 86,745 shares remains material for tracking insider alignment with shareholders.

Corporate Governance Analyst

Transactions were executed by the CFO and reported promptly by attorney-in-fact.

The filer is identified as the company's Chief Financial Officer, and the Form 4 was signed by an attorney-in-fact on 10/02/2025. Timely filing within one day of signature is consistent with Section 16 reporting requirements.

The option expiry of 11/14/2025 suggests near-term instrument maturity; holdings and disclosed vesting (1/3 per year) clarify remaining economic exposure from prior grants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	10/01/2025		M(1)		2,000	A	$101.64	89,745	D
ResMed Common Stock	10/01/2025		S(1)		3,000	D	$274.36	86,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	10/01/2025		M			2,000	11/11/2019(2)	11/14/2025	ResMed Common Stock	2,000	$0	2,000	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

2. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Mike J. Rider, attorney-in-fact for Mr. Sandercock	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did RMD CFO Brett Sandercock report on 10/01/2025?

He exercised 2,000 options at $101.64 and sold 3,000 shares at $274.36, leaving 86,745 shares beneficially owned.

Were these trades part of a pre-arranged trading plan for RMD insiders?

Yes. The Form 4 states the transactions were conducted under a Rule 10b5-1 plan adopted on 2/19/2025.

When do the exercised options expire?

The options underlying the exercise expire on 11/14/2025; they first became exercisable on 11/11/2019.

How many shares does the CFO own after these transactions?

The filing reports a beneficial ownership total of 86,745 shares following the 10/01/2025 transactions.

Who signed the Form 4 for Brett Sandercock?

The Form 4 was signed by Mike J. Rider, attorney-in-fact, on 10/02/2025.